{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:09:15Z","timestamp":1745467755921,"version":"3.40.4"},"reference-count":6,"publisher":"Media Sphere Publishing House","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rus. Ann. Ophthal."],"published-print":{"date-parts":[[2024,4,23]]},"abstract":"<jats:p>Purpose. This study evaluates the efficacy of intravitreal injections (IVI) of faricimab in patients with neovascular age-related macular degeneration (nAMD) and retinal pigment epithelium detachment (RPED) resistant to other anti-VEGF agents. Material and methods. The study included 61 patients (61 eyes) with nAMD previously treated with aflibercept and\/or brolucizumab IVIs. Three groups were formed: group 1 received aflibercept IVI (32 eyes), group 2 received brolucizumab IVI (14 eyes), and group 3 received aflibercept followed by brolucizumab IVI (15 eyes). All patients received four monthly loading injections of faricimab (Vabysmo, F. Hoffmann-La Roche Ltd, Switzerland) at a dose of 0.05 ml (6 mg), with disease activity assessed at month 4. For active disease, injections were administered at 4-week intervals; for inactive disease, injections were done at 8-week intervals. Results. In group 1, significant improvement was observed in all parameters by month 4 (p&lt;0.05), accompanied by an increase in visual acuity. Similar findings were recorded at month 6. In group 2, no statistically significant change in best-corrected visual acuity (BCVA) was found; however, a notable reduction in central retinal thickness and maximum RPED height was seen at both months 4 and 6, due to decrease in fibrous and fibrovascular layers (p&lt;0.05). No signs of prechoroidal cleft were detected. In group 3, monthly IVI resulted in reductions in all parameters except prechoroidal cleft height (p&gt;0.05), although by month 6 the values returned to baseline pre-treatment levels (p&gt;0.05). Conclusions. Intravitreal injections of faricimab may prove to be an effective treatment for nAMD in patients resistant to other anti-VEGF agents.<\/jats:p>","DOI":"10.17116\/oftalma202414006163","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T05:49:26Z","timestamp":1735364966000},"page":"63","source":"Crossref","is-referenced-by-count":0,"title":["Management of patients with treatment-resistant neovascular age-related macular degeneration"],"prefix":"10.17116","volume":"140","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5507-8775","authenticated-orcid":false,"given":"M.V.","family":"Budzinskaya","sequence":"first","affiliation":[{"name":"Krasnov Research Institute of Eye Diseases","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7390-759X","authenticated-orcid":false,"given":"A.A.","family":"Plyukhova","sequence":"additional","affiliation":[{"name":"Krasnov Research Institute of Eye Diseases","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2854-4654","authenticated-orcid":false,"given":"M.A.","family":"Makarova","sequence":"additional","affiliation":[{"name":"Krasnov Research Institute of Eye Diseases","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1292-9629","authenticated-orcid":false,"given":"A.P.","family":"Sorokin","sequence":"additional","affiliation":[{"name":"Eye Microsurgery Clinic of the Industry Clinical Diagnostic Center of PAO GAZPROM","place":["Moscow, Russia"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"6743","reference":[{"key":"key-10.17116\/oftalma202414006163-1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0895-z"},{"key":"key-10.17116\/oftalma202414006163-2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00010-1"},{"key":"key-10.17116\/oftalma202414006163-3","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-023-06222-x"},{"key":"key-10.17116\/oftalma202414006163-4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12155145"},{"key":"key-10.17116\/oftalma202414006163-5","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-024-06421-0"},{"key":"key-10.17116\/oftalma202414006163-6","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S409822"}],"container-title":["Russian Annals of Ophthalmology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T08:41:01Z","timestamp":1745397661000},"score":1,"resource":{"primary":{"URL":"https:\/\/mediasphera.ru\/issues\/vestnik-oftalmologii\/2024\/6\/10042465X2024061063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":6,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12,28]]}},"alternative-id":["10.17116\/oftalma202414006163"],"URL":"https:\/\/doi.org\/10.17116\/oftalma202414006163","relation":{},"ISSN":["0042-465X"],"issn-type":[{"type":"print","value":"0042-465X"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}